Identification of ubiquitination site in BCL-XL after PROTAC DT2216 treatment

ABSTRACT: The availability of a suitable lysine for PROTAC-mediated ubiquitination can also determine the degradative ability of a protein target and the selectivity of a PROTAC. PROTAC DT2216 selectively triggers ubiquitination and degradation of BCL-XL. In this study, we identify K87 is the key ubiquitinated lysine under DT2216 treatment through LC-MS/MS.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Disease Free

SUBMITTER: Dongwen Lv  

LAB HEAD: Dongwen Lv

PROVIDER: PXD015454 | Pride | 2019-10-08

REPOSITORIES: Pride